Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50 Day Moving Average – What’s Next?

Posted by Francis Steltz on Jun 13th, 2026

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report)’s share price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.83 and traded as low as $3.43. Voyager Therapeutics shares last traded at $3.50, with a volume of 540,804 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, May 26th. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Read Our Latest Analysis on VYGR

Voyager Therapeutics Stock Performance

The stock’s fifty day moving average is $3.83 and its two-hundred day moving average is $3.94. The firm has a market cap of $211.47 million, a price-to-earnings ratio of -1.78 and a beta of 1.25.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The business had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $8.79 million. Sell-side analysts predict that Voyager Therapeutics, Inc. will post -1.66 earnings per share for the current year.

Insider Buying and Selling at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 11,511 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the sale, the chief executive officer owned 472,549 shares of the company’s stock, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of Voyager Therapeutics

Large investors have recently modified their holdings of the company. EcoR1 Capital LLC increased its stake in Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock valued at $15,731,000 after buying an additional 3,332,544 shares during the period. Opaleye Management Inc. acquired a new position in Voyager Therapeutics during the 4th quarter valued at about $4,704,000. AQR Capital Management LLC increased its stake in Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after buying an additional 317,927 shares during the period. Renaissance Technologies LLC increased its stake in Voyager Therapeutics by 95.0% during the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after buying an additional 281,574 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after buying an additional 206,758 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.